Article
US FDA panel backs accelerated approval for Biogen's ALS drug
Rating:
0.0
Views:
58
Likes:
1
Library:
1
A panel of advisers to the U.S. drug regulator voted that data on Biogen Inc's experimental treatment for ALS, also known as Lou Gehrig's disease, shows that the drug could work, potentially paving the way for an accelerated approval.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value